Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.29 USD
Change Today -0.31 / -0.95%
Volume 1.8M
DEPO On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 07/27/15 All times are local (Market data is delayed by at least 15 minutes).

depomed inc (DEPO) Snapshot

Open
$32.49
Previous Close
$32.60
Day High
$32.69
Day Low
$31.95
52 Week High
07/21/15 - $33.74
52 Week Low
08/1/14 - $9.85
Market Cap
1.9B
Average Volume 10 Days
2.0M
EPS TTM
$1.39
Shares Outstanding
60.0M
EX-Date
--
P/E TM
23.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for DEPOMED INC (DEPO)

depomed inc (DEPO) Related Businessweek News

No Related Businessweek News Found

depomed inc (DEPO) Details

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.

324 Employees
Last Reported Date: 02/26/15
Founded in 1995

depomed inc (DEPO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $620.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $374.8K
Senior Vice President and General Counsel
Total Annual Compensation: $396.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $211.9K
Senior Vice President of Business Development
Total Annual Compensation: $316.7K
Compensation as of Fiscal Year 2014.

depomed inc (DEPO) Key Developments

DepoMed Inc., Horizon Pharma plc - M&A Call

To consider proposal to acquire Depomed

DepoMed Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 03:00 PM

DepoMed Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 03:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

DepoMed Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:00 AM

DepoMed Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 10:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: August J. Moretti, Chief Financial Officer, Principal Accounting Officer and Senior Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $32.29 USD -0.31

DEPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $34.12 USD +0.41
Cosmo Pharmaceuticals SA SFr.164.30 CHF -0.70
Emergent BioSolutions Inc $32.79 USD -0.02
Insys Therapeutics Inc $42.79 USD -0.55
Nektar Therapeutics $12.42 USD -0.36
View Industry Companies
 

Industry Analysis

DEPO

Industry Average

Valuation DEPO Industry Range
Price/Earnings 21.1x
Price/Sales 5.6x
Price/Book 5.4x
Price/Cash Flow 17.4x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit www.depomedinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.